Viridian Therapeutics (VRDN) announced the appointment of Jeff Ajer to its Board of Directors. Ajer most recently served as the Executive Vice President and Chief Commercial Officer at BioMarin Pharmaceutical (BMRN)
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics Enters New $300M Sale Agreement
- Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges
- Viridian Therapeutics: Promising Pipeline and Strategic Progress Support Buy Rating
- Viridian Therapeutics: Promising Market Position and Growth Prospects Justify Buy Rating
- Viridian Therapeutics Reports Strong Progress and Financials